These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 2117809

  • 1. Immunological follow-up of renal allograft recipients treated with the BMA 031 (anti-TCR) monoclonal antibody.
    Chatenoud L, Ferran C, Legendre C, Kurrle R, Kreis H, Bach JF.
    Transplant Proc; 1990 Aug; 22(4):1787-8. PubMed ID: 2117809
    [No Abstract] [Full Text] [Related]

  • 2. Immunologic monitoring in OKT3-treated kidney graft recipients.
    Zlabinger GJ, Maurer D, Ulrich W, Meron G, Pohanka E, Kovarik J.
    Transplant Proc; 1990 Aug; 22(4):1777-8. PubMed ID: 2117807
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The incidence and quantity of antiidiotypic antibody formation after OKT3 monoclonal therapy in heart-transplant recipients.
    Hesse CJ, Heyse P, Stolk BJ, Balk AH, Jutte NH, Mochtar B, Weimar W.
    Transplant Proc; 1990 Aug; 22(4):1772-3. PubMed ID: 2117805
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Suppression of the humoral response to anti-CD3 mAB by pretreatment with anti-CD4 mAB.
    Hirsch R, Chatenoud L, Gress RE, Bach JF, Sachs DH, Bluestone JA.
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1015-6. PubMed ID: 2523111
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Acute toxicity of anti-CD3 monoclonal antibody in mice: a model for OKT3 first dose reactions.
    Alegre M, Depierreux M, Florquin S, Najdovski T, Vandenabeele P, Abramowicz D, Leo O, Deschodt-Lanckman M, Goldman M.
    Transplant Proc; 1990 Aug; 22(4):1920-1. PubMed ID: 2143864
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
    Norman DJ, Barry JM, Bennett WM, Munson JL, Meyer M, Henell K, Kimball J, Hubert B.
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alpha/beta-T cell receptor.
    Knight RJ, Kurrle R, McClain J, Racenberg J, Baghdahsarian V, Kerman R, Lewis R, van Buren CT, Kahan BD.
    Transplantation; 1994 Jun 15; 57(11):1581-8. PubMed ID: 8009591
    [Abstract] [Full Text] [Related]

  • 16. Review and preview of anti-T-cell antibodies.
    Helderman JH.
    Transplant Proc; 1995 Oct 15; 27(5 Suppl 1):8-9. PubMed ID: 7482824
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
    Goldstein G.
    Transplant Proc; 1987 Apr 15; 19(2 Suppl 1):1-6. PubMed ID: 3105134
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.